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Background: Ceruloplasmin is a ferroxidase expressed in the central nervous system both as soluble form in the
cerebrospinal fluid (CSF) and as membrane-bound GPI-anchored isoform on astrocytes, where it plays a role in iron
homeostasis and antioxidant defense. It has been proposed that ceruloplasmin is also able to activate microglial
cells with ensuing nitric oxide (NO) production, thereby contributing to neuroinflammatory conditions. In light of
the possible role of ceruloplasmin in neurodegenerative diseases, we were prompted to investigate how this protein
could contribute to microglial activation in either its native form, as well as in its oxidized form, recently found
generated in the CSF of patients with Parkinson’s and Alzheimer’s diseases.
Methods: Primary rat microglial-enriched cultures were treated with either ceruloplasmin or oxidized-ceruloplasmin,
alone or in combination with lipopolysaccharide (LPS). Production of NO and expression of inducible nitric oxide
synthase (iNOS) were evaluated by Griess assay and Western blot analysis, respectively. The productions of the
pro-inflammatory cytokine IL-6 and the chemokine MIP-1α were assessed by quantitative RT-PCR and ELISA.
Results: Regardless of its oxidative status, ceruloplasmin by itself was not able to activate primary rat microglia.
However, ceruloplasmin reinforced the LPS-induced microglial activation, promoting an increase of NO production, as
well as the induction of IL-6 and MIP-1α. Interestingly, the ceruloplasmin-mediated effects were observed in the
absence of an additional induction of iNOS expression. The evaluation of iNOS activity in primary glial cultures
and in vitro suggested that the increased NO production induced by the combined LPS and ceruloplasmin treatment
is mediated by a potentiation of the enzymatic activity.
Conclusions: Ceruloplasmin potentiates iNOS activity in microglial cells activated by a pro-inflammatory stimulus,
without affecting iNOS expression levels. This action might be mediated by the activation of a yet unknown Cp
receptor that triggers intracellular signaling that cross-talks with the response elicited by LPS or other pro-inflammatory
stimuli. Therefore, ceruloplasmin might contribute to pathological conditions in the central nervous system by
exacerbating neuroinflammation.
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Ceruloplasmin (Cp) is one of the major copper-binding
proteins in the blood and, due to its ferroxidase activity,
plays a role in iron metabolism. Cp is secreted in the
plasma by the liver, but it is produced also by the epithe-
lial cells of the choroid plexus and released in the cere-
brospinal fluid (CSF) [1]. In the brain, a GPI-anchored
form of Cp is present on astrocytes [2] and leptomenin-
geal cells [3], where it may contribute to iron homeosta-
sis and antioxidant defense, converting toxic ferrous iron
into ferric form [4,5]. We previously reported that Cp
undergoes oxidative modifications in the CSF of Parkin-
son’s disease (PD) and Alzheimer’s disease (AD) patients
[6], due to the oxidative environment of pathological
CSF [7,8]. Oxidized Cp (Cp-ox) loses its ferroxidase activ-
ity, which in turn promotes intracellular iron retention in
neurons [6] and gains integrin-binding and signaling prop-
erties, due to oxidation-induced structural changes [9,10].
Microglial cells are immune-competent cells derived
from the monocyte/macrophage lineage and distributed
throughout the central nervous system (CNS). They rep-
resent the first line of defense, being activated in response
to different stimuli such as cerebral ischemia, infection,
neurodegenerative disease and endotoxins [11,12]. After
activation, microglial cells trigger the inflammatory pro-
cesses characterized by secretion of pro-inflammatory cy-
tokines, chemokines, elements of complement cascade
and by increased expression of several enzymes re-
sponsible for the production of either reactive-oxygen
or -nitrogen species (ROS and RNS) [13]. These react-
ive molecules are necessary at low concentrations for
the defense mechanisms against invading microbial and
viral pathogens, but at higher concentrations they are
toxic for neurons and can accelerate and exacerbate the
progression of neurodegeneration [14-18].
Several neurodegenerative disorders, including Alzheimer’s
and Parkinson’s diseases, are characterized by high levels of
ROS and RNS in brain, serum and CSF [18-22], suggesting
that neurodegenerative disease may also be driven by an
over-activation of microglial cells.
Microglial cells express Toll-like receptors (TLRs 1 to
9), responsible for the pro-inflammatory pathway activa-
tion induced by microbes, viruses and tissue damage
[13,23,24]. In addition to these common stimulants,
microglia can be activated by disease-specific proteins,
such as β-amyloid and α-synuclein [22,25,26], and by
soluble mediators released by dying neurons (for example,
matrix metalloproteinase-3, calpain, neuromelanin, frac-
talkine) [17,27]. Microglial cells can also be stimulated by
lipopolysaccharide (LPS), the principal cell-wall compo-
nent of Gram-negative bacteria [23,24,28,29]. The dele-
terious effects of LPS might also be mediated by its
interaction with TLRs present on brain endothelial
cells, which, in turn, can activate adjacent microglialcells by releasing nitric oxide (NO) or other mediators
[30-34]. Therefore, a possible role of LPS-mediated
neuroinflammation has been proposed also in the pro-
gression of PD and AD [35-39].
It has been reported that Cp is able to activate micro-
glia with ensuing induction of inducible nitric oxide syn-
thase (iNOS), production of NO and increase in the
levels of mRNAs encoding interleukins and enzymes
such as cyclooxygenase-2 or NADPH oxidase [40]. For
this reason, we were prompted to investigate whether
Cp, as well as the oxidized Cp found in the CSF of PD
and AD patients, could have a role in exacerbating the
pro-inflammatory pathological conditions via microglial
cell activation.
Here we show that Cp alone, regardless of its oxidative
status, is not able to activate microglial cells, but can po-
tentiate/synergize the LPS-induced microglial activation,
increasing the production of NO, the induction of IL-6
and MIP-1α mRNAs and the secretion of IL-6. These ef-
fects were observed in the absence of further induction
of iNOS expression, and sustained by the potentiation of
the iNOS activity.Methods
Material
Ceruloplasmin from human plasma was purchased from
Enzo Life Sciences (Farmingdale, NY, USA), the presence
of endotoxin contaminant was evaluated using the Lim-
ulus Amebocyte Lysate (LAL) Pyrogent® Plus Single test
(Lonza, Walkersville, MD, USA) and results found to be
0.006 EU/μg of Cp. E. coli LPS, Nω-Nitro-L-arginine me-
thyl ester hydrochloride (L-NAME) and other chemicals,
when not specified, were obtained from Sigma-Aldrich
(St Louis, MO, USA). Recombinant rat IL-1β, TNF-α,
INF-γ and granulocyte macrophage colony-stimulating
factor (GM-CSF) were from R&D Systems (Minneapolis,
MN, USA). All the reagents were resuspended in apyro-
genic endotoxin-free water for clinical injectable prepara-
tions (SALF-Laboratorio Farmacologico, Bergamo, Italy).
The antibodies used in the study were mouse monoclonal
anti-iNOS (BD Biosciences, San Jose, CA, USA), mouse
monoclonal anti-α-tubulin (Sigma-Aldrich, St Louis, MO,
USA). Polyclonal goat anti-mouse Ig horseradish peroxid-
ase (HRP)-conjugated (DAKO, Carpinteria, CA, USA) was
used as the secondary antibody.Cell cultures
The animal use procedures, performed according to the
EC Directive 86/609/EEC, were approved by the Institu-
tional Animal Care and Use Committee of the San Raf-
faele Scientific Institute. Animals were sacrificed after
gentle carbonarcosis (by slowly rising CO2 inside the
cage) to minimize pain and discomfort.
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from cerebral cortices of two-day-old Sprague-Dawley
rat pups, as described previously [41,42]. After removing
the meninges, cortices were cut into small sections and
washed in Hank’s Balanced Salt Solution supplemented
with Hepes/Na pH 7.4 (10 mM), MgSO4 (12 mM), 50
U/ml penicillin and 50 μg/ml streptomycin. Then, they
were dissociated with 2.5 mg/ml trypsin type IX in the
presence of 1 mg/ml deoxyribonuclease (Calbiochem,
San Diego, CA, USA) for 10 minutes at 37°C in two sub-
sequent steps and the cell suspension obtained was di-
luted 1:1 in medium containing 10% horse serum (PAA
Laboratories, Dartmouth, MA, USA). The cell suspen-
sion was spun (50 g for 15 minutes) and cells were put
in culture in Minimum Essential Medium Eagle (Lonza,
Walkersville, MD, USA) supplemented with 10% horse
serum, 33 mM glucose, 2 mM Glutamax (Gibco, Grand
Island, NY, USA), 50 U/ml penicillin, 50 μg/ml strepto-
mycin and 20 ng/ml GM-CSF. Cells were maintained in
75 cm2 flasks (approximately 1 flask for 3 pups) at 37°C
in a humidified 5% CO2 incubator. Microglia cells were
obtained by gentle manual shaking of the flasks two to
three days after dissection. Detached cells (about 75 to
85% microglia with a 15 to 25% astrocytic contamin-
ation) were plated with fresh medium containing GM-
CSF on 12-well plates coated with poly-l-lysine (100 μg/ml).
Purity of highly-enriched microglial cells was assessed
by morphological examination performed by immuno-
fluorescence for ionized calcium-binding adaptor mol-
ecule 1 (polyclonal rabbit anti-IBA1 (Wako, Richmond,
VA, USA) used at 1:250 dilution), and glial fibrillary acidic
protein (monoclonal mouse anti-GFAP (Sigma-Aldrich,
St Louis, MO, USA), used at 1:250 dilution), markers
for microglia and astrocytes respectively; in all the ex-
periments purity ranged between 75 to 85%.
The resting state of unstimulated microglia was con-
firmed by the almost undetectable levels of IL-6 secre-
tion and iNOS expression.
Cp oxidation and Cp denaturation
Oxidation and deamidation of Cp, which promote its
integrin-binding properties [10], were performed by in-
cubating purified Cp at 37°C in 10 mM hydrogen perox-
ide solution and 100 mM ammonium bicarbonate, pH 8.5
as described in [6,10]; this product is referred in the text
as oxidized-Cp (Cp-ox). Denaturation of Cp was per-
formed by heating Cp at 100°C for 15 minutes and re-
ferred in the text as Cp-heated.
Cell treatments
Stimuli were administered directly to the culture medium
as follows: rat cortical highly-enriched microglia cultures
were stimulated in serum-free fresh medium containing
33 mM glucose, 2 mM glutamine, 50 U/ml penicillin,50 μg/ml streptomycin with: LPS (10 ng/ml), mix of IL-1β
(10 ng/ml) and TNF-α (30 ng/ml) (referred in text as
2CKs), mix of IL-1β (10 ng/ml), TNF-α (30 ng/ml) and
INF-γ (20 ng/ml) (referred in text as 3CKs), Cp from human
plasma (1 to 20 μg/ml) and oxidized-Cp (1 to 20 μg/ml) for
24 hours at 37°C. Cytokine concentrations were used ac-
cording to the literature as to obtain maximal effect on glial
cells (see [43] and references therein) [41,44]. In some cases
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME),
an arginine-analog that selectively inhibits iNOS function
was administered at different concentrations (0.1, 0.25
and 1 mM) 1 hour before pro-inflammatory stimuli ad-
ministration and left for the entire duration of the
treatment.
Nitrite assay
Nitrite present in culture supernatants was measured as
an indirect indicator of NO production using the Griess
assay [45]. An aliquot (100 μl) of culture medium was
mixed with an equal volume of Griess reagent (1:1 mix-
ture of 1% sulfanilamide in 5% orthophosphoric acid and
0.1% naphtylenethylenediamine dihydrochloride in H2O)
in a 96-multiwell plate. Plates were gently shaken for
1 minute and the absorbance at 550 nm was measured
using a microplate reader. Nitrite concentration in the
samples was interpolated with a sodium nitrite standard
curve ranging from 0 to 100 μΜ.
Quantitative real-time PCR
RNA was extracted with TRIzol® according to manufac-
turer’s protocol (Invitrogen, Carlsbad, CA, USA). After
extraction with chloroform and ethanol precipitation,
RNA pellets were air-dried for 5 minutes, resuspended
in 20 μl of RNase-free water and stored at −80°C. To
evaluate the purity of RNA, the ratio of absorptions at
260 versus 280 nm (for contamination by other nucleic
acids and protein) and ratio at 230 versus 260 nm (for
contamination by organic compounds), were assessed with
spectrophotometer (Eppendorf, Hauppauge, NY, USA).
The RNA quality was assessed by electrophoresis.
Reverse transcription (RT) was performed using Super-
script III Retrotranscription Kit (Invitrogen, Carlsbad, CA,
USA) and random hexamers as primers, following manu-
facturer instruction. RT was carried out for 50 minutes at
50°C followed by incubation for 5 minutes at 85°C. Single
strand cDNA was obtained digesting complementary
RNA strand with provided RNase H for 20 minutes at
37°C.
Real-time comparative PCR was performed on a Light-
Cycler® 480 Real-Time PCR System (Roche), using 500 ng
of cDNAs as templates and LightCycler® 480 DNA SYBR
Green I Master Mix (Roche) according to the manufac-
turer’s instructions. Primers were designed using Primer
Express Software v3.0 (Applied Biosystems, Foster City,
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Italy). Each primer was tested to evaluate efficiency and
specificity (range 91 to 103%); the RT-PCR amplification
was carried out according to our previous report [41] with
a denaturation step at 95°C for 10 minutes, followed by
45 cycles of amplification. Each cycle consisted of a
denaturation step (95°C, 10 seconds), an annealing
step (60°C, 25 seconds) and an elongation step (72°C,
15 seconds). After amplification, a melting step was
performed (95°C for 30 seconds, 60°C for 1 minute).
Determination of crossing points and melting peaks
was performed with LightCycler 480 Software (version
1.5.0.39, Roche, Basel, Switzerland). Primers forward and
reverse were used both at a 0.5 μM concentration and the
sequences were: ccaccgctgcccttgctgtt and cacccggctgggag
caaagg for the gene encoding macrophage inflammatory
protein-1 alpha (MIP-1α); gtatgaacagcgatgatgcact and gaa
gaccagagcagattttcaatag for the gene encoding IL-6; cagaag
gacgtgaaggatgg and cagtggtcttggtgtgctga for 18S rRNA,
that is the gene coding for 18S ribosomal RNA, used as
internal reference for normalization.
Each sample was analyzed in duplicate. For each sam-
ple, relative expression of target genes was calculated
based on real-time PCR efficiencies (E) and the thresh-
old cycle (Ct) difference (Δ) of a treated sample versus a
control (ΔCtcontrol–sample) and expressed relative to the ref-
erence genes chosen, in according to the 2–ΔΔCt method.
Western blot analysis
Cells were lysed on ice in lysis buffer (15 mM PBS, 2%
NP-40, 0.2% SDS, 10 mM EDTA, 1% protease inhibitor
cocktail, 1% phosphatase inhibitor cocktail). After centrifu-
gation, the supernatant was collected and protein concen-
tration evaluated by Bradford assay (Bio-Rad Laboratories,
Hercules, CA, USA). Lysates containing 10 to 20 μg of pro-
teins were re-suspended in Laemmli buffer, then proteins
were resolved on 10% acrylamide SDS-polyacrylamide gel
electrophoresis and then electro-transferred to nitrocel-
lulose membranes for Western blot (WB) analysis. Protein
transfer was evaluated by red Ponceau S staining (Sigma-
Aldrich, St Louis, CA, USA). The membranes were
blocked in a 5% milk solution in TBS (0.1% Tween 20)
and incubated 12 hours at 4°C with primary antibodies.
The reactivity was revealed by incubation (1 hour at
20°C) with HRP-conjugated secondary rabbit anti-goat
IgG followed by chemiluminescence reaction performed
with electrochemiluminescence (ECL) detection reagents
(GE Healthcare, Little Chalfont, UK) and film exposure.
The WB bands reactivities were quantified by densitom-
etry analysis using a G-Box scanner and the associated
GeneSys software (Syngene, Cambridge, UK). The films
were scanned and the bands optical density was measured
with GeneTools software (Syngene, Cambridge, UK). Ex-
pression of α-tubulin was used as a loading control.Interleukin-6 determination
IL-6 was measured by ELISA kit (KRC0061; Invitrogen,
Carlsbad, CA, USA), according to manufacturer’s in-
structions, using 50 μl of supernatants collected from
microglial cultures after different treatments.
Nitric oxide synthase activity
NOS activity was evaluated with the Colorimetric Nitric
Oxide Assay Kit from Oxford Biomedical Research (Oxford,
UK). The assay measures the capability of NOS, present in
cell lysates, to convert L-arginine to citrulline and NO and
with a colorimetric reaction reveals nitrite and nitrate pro-
duction as read-out products. For the assay, 100 μg of
proteins were used from primary rat microglial-enriched
cultures treated for 24 hours with LPS 10 ng/ml, alone or
in combination with Cp 20 μg/ml. Cells were lysed on ice
in PBS containing 0.5% Triton X-100, 1% protease inhibi-
tor cocktail, 1% phosphatase inhibitor cocktail. After cen-
trifugation, the lysate supernatant was collected, protein
concentrations determined by Bradford assay (Bio-Rad
Laboratories, Hercules, CA, USA), and lysates were used
for activity detection.
Statistical analysis
Continuous data were evaluated by Mann-Whitney test,
since they did not pass the normality test for Gaussian dis-
tribution, as assessed by the Kolmogorov-Smirnov test;
two-tailed P-value was used for the comparison of two
means and standard error; the mean values were calcu-
lated using pooled data from different experiments. In all
analyses, P < 0.05 was considered to be statistically signifi-
cant. The analysis was performed with Prism V4.03 soft-
ware (GraphPad Inc., La Jolla, CA, USA).
Results
Cp and Cp-ox potentiate LPS-induced NO production in
the absence of additional iNOS induction
Primary rat microglia-enriched cultures treated with LPS
at 10 ng/ml showed an activated phenotype, as expected,
and displayed both iNOS expression and nitrite increase
(15.9 ± 2 μM) in the medium (Figure 1A-B). On the con-
trary, treatment of cells with either Cp, oxidized-Cp or
with the control BSA stimulus (20 μg/ml), did not trig-
ger activation, as assessed by nitrite dosage in the cell
medium (Figure 1A). As expected, the same treatments
did not induce iNOS expression as evaluated by WB
(Figure 1B). Interestingly, the concomitant treatment of
LPS with Cp or with Cp-ox produced a synergistic effect
that significantly increased (P < 0.0001, Mann-Whitney
test) the amount of nitrite detected in the medium (30 ±
2 μM), even in the absence of a further induction of the
iNOS enzyme (Figure 1A-B). A similar synergistic effect
was not observed if microglial cells were concomitantly
treated with LPS and BSA (Figure 1A-B).
Figure 1 Cp and Cp-ox potentiate lipopolysaccharide (LPS)-induced nitric oxide (NO) production in the absence of additional inducible
nitric oxide synthase (iNOS) induction. (A) Nitrite production assessed by Griess assay in culture medium of microglial cells after 24 hours of
treatment with medium alone (Ctrl), LPS (10 ng/ml), ceruloplasmin (Cp), oxidized-ceruloplasmin (Cp-ox), heat-denatured ceruloplasmin (Cp-heated)
and BSA alone (all at 20 μg/ml) or in combined treatment with LPS. Results are expressed as μM of nitrite present in culture medium that reflects the
NO-production. (B) Western blot analysis of inducible nitric oxide synthase expression in microglial cells after treatments as described in
(A). Densitometric optical density (OD) for iNOS bands were normalized with α-tubulin expression and are reported as ratio of the OD of
specific treatments versus OD of LPS treatment. Bottom panels are representative of one experiment. (C) Dose-dependent analysis of Cp
co-treatment in the potentiation of the LPS-induced nitrite production. Microglial cells were treated with a steady amount of LPS (10 ng/ml)
plus increasing concentrations of Cp (1, 2.5, 5, 10 and 20 μg/ml). The nitrite production was reported as ratio of nitrite production in specific treatment
versus LPS treatment. (D) Western blot analysis for iNOS expression in microglial cells upon LPS treatment combined with dose-dependent increase of
Cp. Densitometric analysis was reported as described in (B). Bottom panels are representative of one experiment. Three/four independent experiments
(as indicated n =) were performed and mean values, calculated using pooled data from different experiments, with standard error are reported.
Statistical P-values were evaluated by non-parametric Mann-Whitney test. In all analyses, P < 0.05 was considered to be statistically significant.
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denatured Cp to microglial cells indicated that the ob-
served potentiating effect of Cp was due to Cp protein
features. Indeed the loss of Cp protein conformation re-
sulted in a significant failure (P = 0.0004, Mann-Whitney
test) of the synergistic effect with LPS (Figure 1A-B).
Analysis of the synergy between Cp and LPS on activa-
tion showed a dose-dependent increase of nitrite pro-
duction, evaluated in rat primary microglial cells treated
with 10 ng/ml LPS plus increasing concentration of Cp
(0, 1, 2.5, 5, 10, 20 μg/ml). Results showed a significant
increase in the nitrite production already at 5 μg/ml Cp
(P = 0.013, Mann-Whitney test), a concentration that is con-
sistent with the physiological Cp concentration in the CSF(Figure 1C). Also in this case, WB analysis showed no signifi-
cant differences in iNOS expression in cells treated with dif-
ferent Cp concentrations in addition to LPS (Figure 1D).
To confirm that the observed effects were attributable
to microglial cells activation and not to the few astro-
cytes present in the cultures, we performed LPS and
LPS + Cp treatments on primary astrocytes cultures,
showing neither production of nitrite nor iNOS expres-
sion (data not shown).
Cp and Cp-ox strengthen cytokines production in
LPS-induced microglial activation
In order to assess whether NO production was associ-
ated with a general activation of microglial cells, we
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typic pro-inflammatory cytokine IL-6 and chemokine
MIP-1α. LPS treatment induced the expression of these
genes, while neither Cp alone nor BSA treatments re-
sulted to be effective (Figure 2A-B). Similar to what we
observed for NO production, co-treatment with LPS and
Cp showed a synergistic effect, further increasing the ex-
pression of both IL-6 and MIP-1α (Figure 2A-B).
The synergistic effect of Cp co-treatment in the induc-
tion of IL-6 cytokine expression was also confirmed at
protein level by ELISA test. Indeed, Cp caused a signifi-
cant increase in the amount of secreted IL-6 in the cul-
ture supernatants in comparison to LPS alone or LPS +
BSA (Figure 2C).
No differences were observed between Cp and Cp-ox
treatment (data not shown), thus definitively ruling out
the initial hypothesis of a possible gain of different func-
tion in microglial stimulation by Cp-ox.
The synergistic effect of Cp in microglia activation
depends on the presence of iNOS
Induction of iNOS protein in microglia occurs in re-
sponse to LPS, but microglia can also be activated by
other stimuli. To investigate whether the observed syn-
ergistic effect of Cp was specific for LPS activation, we
concomitantly treated with Cp primary microglia cul-
tures stimulated with mix of different cytokines (CKs),
IL-1β and TNF-α (herein after referred to as ‘2-CKs’), or
with IL-1β, TNF-α and IFN-γ (hereinafter referred to as
‘3-CKs’) known to be respectively unable and able to in-
duce iNOS expression [46]. The use of 2-CKs alone
showed very low nitrite production with respect to LPS
stimulation, and the results were similar when 2-CKs
were used in combination with Cp (Figure 3A); in both
conditions iNOS protein expression was not detectable
(Figure 3B). On the contrary, the treatment with 3-CKs
resulted in a nitrite production comparable to those no-
ticed in microglia stimulated with LPS, and when 3-CKs
were supplemented with Cp, a synergistic effect on nitrite
production, comparable to that detected with LPS + Cp,
was observed (Figure 3A). As expected, the use of IFN-γ
together with IL-1β and TNF-α induced the expression of
iNOS, and, similarly to the LPS + Cp treatment, no further
expression changes were induced by concomitant treat-
ment with Cp (Figure 3B). mRNA expression of both IL-6
and MIP-1α, and the release of IL-6 protein in the
medium, was found to be weak after microglia were incu-
bated with either 2-CKs or 3-CKs, and were not modified
by the addition of Cp (data not shown).
Increased NO production fostered by LPS + Cp co-treatment
depends on incremented iNOS activity
In order to investigate whether increased NO production
induced by Cp co-treatment was dependent on themodulation of iNOS activity, we utilized L-NAME, an
arginine-analog that selectively inhibits iNOS function.
We found that at low concentration (0.1 mM) L-NAME
produced only a small reduction in the amount of NO
produced by LPS stimulation (25% reduction compared to
cells treated with LPS alone, not statistically significant).
On the contrary, L-NAME pre-treatment was more effect-
ive in reducing NO production in cells concomitantly
treated with LPS and Cp (63% reduction of the increased
NO production over LPS treatment alone, P = 0.0009,
Mann-Whitney test), almost abolishing the synergistic
effect (Figure 4A).
In both LPS and LPS + Cp treatments, in the presence
of L-NAME 0.1 mM, iNOS protein expression levels
remained equal to those observed in the absence of the
iNOS inhibitor (Figure 4B). These results together sug-
gested that the Cp-induced synergistic effect on NO pro-
duction could depend on the modulation of iNOS activity.
Increasing L-NAME concentration to 0.25 mM caused a
strong decrease in NO production in both LPS and LPS +
Cp treatments, resulting also in a reduction in iNOS pro-
tein expression of about 50%, as determined by WB ana-
lysis (Figure 4A-B). At higher L-NAME concentration
(1 mM), the nitrite production was completely abolished,
and the iNOS protein expression was reduced of about
75%, if compared with LPS treatment (Figure 4A-B).
To confirm that the increase of nitrite production ob-
served in LPS + Cp treatment was dependent on an in-
crease in iNOS enzymatic activity, we measured in vitro
the NOS activity in lysates obtained from microglial cells
treated either with LPS alone or LPS + Cp. The mea-
sured activity was normalized by iNOS and α-tubulin ex-
pression, detected by WB analysis. The results showed a
significant increase of about 50% (P < 0.0284, Mann-
Whitney test) in nitrite and nitrate production by iNOS
enzyme present in the lysate of microglial cells treated
with LPS + Cp compared to cells treated with LPS alone
(Figure 4C), despite the presence of equal iNOS expres-
sion levels, as evidenced by WB analysis (Figure 4D).
Discussion
Here we show how microglial activation, following either
LPS or cytokines mixture (IL-1β, TNF-α and IFN-γ)
stimulation, is exacerbated by the concomitant treat-
ment with ceruloplasmin, suggesting that this protein
can act as a co-factor in the inflammation process. Al-
though its role in inflammation is not completely under-
stood, Cp has been reported to be an acute phase
protein with anti-inflammatory properties, because the
Cp levels increased during inflammation/infection [47,48].
Since Cp interacts with metal ions, namely copper and
iron, it is very susceptible to redox changes. Recent work
of our team showed that Cp oxidation, which occurs in
neurodegenerative diseases as a consequence of an
Figure 2 Cp increases cytokines production in lipopolysaccharide
(LPS)-induced microglial activation. (A) Expression of IL-6 cytokine
mRNA assessed by quantitative-PCR in microglial cells after 24 hours of
treatment with medium alone (Ctrl), LPS (10 ng/ml), ceruloplasmin
(Cp), and BSA alone (20 μg/ml) or in combined treatment with LPS.
Results are expressed as mRNA fold change expression levels relative
to expression value obtained for LPS stimulus. (B) Expression of MIP-1α
chemokine mRNA assessed by quantitative PCR in microglial cells as in
(A). Results are expressed as mRNA fold change expression levels
relative to expression value obtained for LPS stimulus. (C) Secretion
of IL-6 cytokine was evaluated by ELISA test in the culture medium of
microglial cells after treatments as in (A). Results are reported as
picograms of protein per milliliter of medium. Three independent
experiments (n = 3) were performed and mean values, calculated
using pooled data from different experiments, with standard error
are reported. Statistical P-values were evaluated by non-parametric
Mann-Whitney test. In all analyses, P < 0.05 was considered to be
statistically significant.
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binding function and triggers intracellular signaling,
that through ERK1/2, Akt and mitogen-activated pro-
tein kinase (MAPK) signaling pathways involvement,
may regulate gene activation, cell cycle and prolifera-
tion [6,10].
Since it has been reported that Cp can be involved in
microglial activation [40], and considering that micro-
glial cells could play a role in many inflammatory and
neurodegenerative processes in the CNS, we investigated
whether Cp and Cp-ox had a role in microglia-mediated
inflammatory reaction. Our results show that Cp poten-
tiated microglial activation, promoting a significant in-
crease in NO production. This effect was dependent on
the expression of iNOS induced by a pro-inflammatory
stimulus (for example, LPS or cytokines), in contrast to
what was previously reported [40]. In fact, in our experi-
mental conditions, Cp alone was not able to induce
microglial activation and NO production. This contrast-
ing observation might depend on various experimental
variables such as the source of purified Cp, as well as
the activation state of microglial cells, depending on cul-
ture conditions before the stimulation. In order to inves-
tigate glial activation in vitro, microglial cells must be in
a ‘resting’ state (that is almost undetectable levels of
basal secretion of pro-inflammatory molecules) until ex-
posed to stimuli. Our culture conditions (for example,
the use of horse serum, the timing of the shaking pro-
cedure, the addition of GM-CSF just after the dissection
procedure, and so on) have been optimized in order to
allow proliferation without inducing ‘basal’ activation in
the absence of stimulation. This allowed us to better
mimic the in vivo situation.
The findings that the oxidation status of Cp has no
measurable effect on the ability of Cp to potentiate iNOS
activity, rule out the initial hypothesis that Cp-ox might
have a role in neuroinflammation in neurodegenerative
Figure 3 The effect of Cp in microglial activation depends on
the presence of inducible nitric oxide synthase (iNOS). (A) Nitrite
production assessed by Griess assay in culture medium of microglial
cells after 24 hours of treatment with medium alone (Ctrl), LPS
(10 ng/ml), IL-1β and TNF-α (2-CKs), or with IL-1β, TNF-α and IFN-γ
(3-CKs) alone or in combination with ceruloplasmin (Cp) (20 μg/ml).
Results are expressed as μM of nitrite present in culture medium that
reflects the nitric oxide (NO)-production. (B) Western blot analysis of
iNOS expression in microglial cells after treatments as in (A).
Densitometric optical density (OD) for iNOS bands were normalized
with α-tubulin expression and are reported as ratio of the OD of
specific treatments versus OD of LPS treatment. Bottom panels are
representative of one experiment. Three/four independent experiments
(as indicated n =) were performed and mean values, calculated using
pooled data from different experiments, with standard error are
reported. Statistical P-values were evaluated by non-parametric
Mann-Whitney test. In all analyses, P < 0.05 was considered to be
statistically significant.
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Nevertheless, a contribution to neuroinflammation in
neurodegenerative diseases of Cp-ox, that has been re-
ported to be on average about 50% of the total Cp
compared to the 20% in healthy subjects [6], could be
indirectly exerted throughout the release, upon oxida-
tion, of the six copper ions coordinated in Cp structure
[1,6,10,49]. Of note, the potentiation of LPS-inducedNO production supported by a second stimulus has
already been described in microglia in the case of the
exposure to metals such as zinc, manganese and co-
balt. However, in these studies, the increase in NO
production was due to a concomitant increase in iNOS
expression [50-53]. Our results indicate that the effect
of Cp on NO production did not rely on an additional
increase of iNOS expression, but rather on a potentiation
of iNOS enzymatic activity. Moreover, the downstream
signaling activated by Cp, not only accomplished the po-
tentiation effect of iNOS activity but, eventually, fostered
the induction of IL-6 and MIP-1α expression.
An open question that needs further investigation is
how Cp mediates the potentiation of iNOS activity; one
possibility, is that Cp, activating an unknown receptor,
triggers an intracellular signaling that interacts with the
response elicited by LPS or other pro-inflammatory stim-
uli. The involvement of p44/42 MAPK kinases (ERK1/2)
has been reported in Cp-mediated induction of iNOS in
microglial cells [40] and it is supported also by our prelim-
inary results (data not shown); these kinases might also
mediate the iNOS activity potentiation induced by Cp
co-stimulation. In fact, the ERK-mediated phosphoryl-
ation of human iNOS on Serine 745 (rat ortholog
Ser742) has been reported to be a stimulator of iNOS
enzymatic activity [54].
Although neuroinflammation is not considered as an
initiating factor in neurodegeneration, evidence obtained
from animal models supports the hypothesis that inflam-
matory responses involving microglia contribute to neu-
rodegenerative diseases progression [14,15,22,23,25,37].
We used LPS as a paradigm for microglial activation that
is usually due to disease-specific proteins and soluble
mediators. In vivo LPS can trigger microglial activation
either directly, entering the CNS through a damaged blood-
brain-barrier (BBB) [24,32,55,56], or indirectly through
molecules released by endothelial cells upon interaction
with bacteria [30,31,33].
If the Cp-mediated reinforcement of microglial activation
occurs in brain, the increased production of neurotoxic
compounds like NO might contribute to neurodegenera-
tion, since NO can react with free radical superoxide to
form peroxynitrite, a powerful oxidizing agent with potent
cytotoxic action [57,58]. The physiological Cp concentra-
tion in CSF is on average 1.5 μg/ml [59], which is lower
than the concentration we found efficacious in producing
the potentiation effect (5 to 20 μg/ml); nevertheless, Cp
concentration can locally increase, as it occurs in some
brain regions after injury or in neurodegenerative disorders
[60-62]. In addition, it must be taken into consideration
that BBB damage could allow both serum penetration and
infiltration of white blood cells, that could further increase
local Cp concentration. In fact, Cp concentration in serum
is ten fold higher than in the CSF, and it has been reported
Figure 4 Increased nitric oxide (NO) production fostered by Cp
treatment in combination with lipopolysaccharide (LPS)
depends on an incremented inducible nitric oxide synthase
(iNOS) activity. (A) Nitrite production assessed by Griess assay in
culture medium of microglial cells after 24 hours of treatment with
medium (Ctrl), LPS (10 ng/ml) alone and in combination with Cp
(20 μg/ml) or the same treatments performed following 1 hour
pre-treatment with increasing concentrations of L-NAME (0.1, 0.25
and 1 mM). Results are expressed as μM of nitrite present in culture
medium that reflects the NO production. Reduction percentage of
nitrite production induced by L-NAME pre-treatment is indicated.
(B) Western blot analysis of iNOS expression in microglial cells
after treatments as in (A). Densitometric optical density (OD) for
iNOS bands was normalized with α-tubulin expression and was reported
as ratio of the OD of specific treatments versus OD of LPS treatment.
Bottom panels are representative of one experiment. (C) Measure
of iNOS activity in the lysate of microglial cells after LPS and LPS + Cp
treatment. Results are reported as the ratio of nitrite and nitrate
production (μM) in the lysate of cells treated with LPS + Cp versus
LPS alone. Nitrite production was normalized by iNOS and α-tubulin
expression levels as revealed by Western blot densitometric analysis.
(D) Representative Western blot analysis of iNOS and α-tubulin
expression in lysates of microglial cells treated with LPS and LPS + Cp
that were used for enzyme activity normalization. Three/four
independent experiments were performed (as indicated n =) and
mean values, calculated using pooled data from different experiments,
with standard error are reported. Statistical P-values were evaluated by
non-parametric Mann-Whitney test. In all analyses, P < 0.05 was
considered to be statistically significant.
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the soluble and the GPI-anchored Cp isoforms [63-65]. The
local increase of Cp concentration due to serum Cp penetra-
tion might also be fostered by the release of copper ions
from the Cp-ox in the neurodegenerative CSF, which in turn
could affect the physiological functions of the brain
barrier systems, contributing to the blood-cerebrospinal
fluid-barrier (BCB) and BBB leakiness found in some neu-
rodegenerative disorders [66,67].
Conclusion
Our results suggest that endogenous Cp, which usually
plays an anti-inflammatory/antioxidant role, if present in
increased concentration could exacerbate the damaging
effect of pro-inflammatory stimuli in brain by modulat-
ing microglial activation.
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